Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
Sponsor: Fujian Medical University Union Hospital
Summary
This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
Official title: Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: an Exploratory Phase II Single-arm Clinical Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2024-07-11
Completion Date
2026-12-01
Last Updated
2025-09-15
Healthy Volunteers
No
Conditions
Interventions
Serplulimab
Serplulimab (300 mg) administered intravenously on day 1 of each 21-day cycle for 2 cycles.
Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)
Paclitaxel (175 mg/m²) and Cisplatin (75 mg/m²) administered intravenously on day 1 of each 21-day cycle for 2 cycles as part of neoadjuvant chemotherapy.
Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
Paclitaxel (50 mg/m²) and Cisplatin (25 mg/m²) administered intravenously on days 1, 8, 15, and 22 of a 4-week cycle as part of concurrent chemoradiotherapy.
Radiotherapy
Radiotherapy at a dose of 40 Gy, delivered in 20 fractions over 4 weeks.
Locations (1)
Fujian Medical University Union Hospital
Fuzhou, Fujian, China